India, conveyed to the US that it had not violated any multilateral trade agreement by issuing compulsory license for Bayer's patented anti cancer drug Nexavar to a local firm so as to make it affordable.
It also asserted that such a move should not be seen as routine by the US.
- In March last year, Hyderabad based NATCO PHARMA was allowed to manufacture and sell cancer treatment drug NEXAVAR at price not exceeding Rs.8,800 for a pack of 120 tablets required for a month treatment as compared to a whopping Rs.2.80Lakh charged by Bayer for its patented Nexavar Drug.
- The German firm has already filed an appeal against the Indian Patent office's order with the Intellectual Property Appellate Board.
- As per the WTO agreement, a Compulsory License can be invoked by a National Government, allowing someone else to produce a patented product or process without the consent of the patent owner in public interest.
Courtesy: THE HINDU
No comments:
Post a Comment